Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Neuroblastoma - Pipeline Review, Q1 2011

VIEWS: 4 PAGES: 53

Neuroblastoma - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Neuroblastoma - Pipeline Review, Q1 2011', provides an overview of the Neuroblastoma therapeutic pipeline. This report provides information on the therapeutic development for Neuroblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroblastoma. 'Neuroblastoma - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - A snapshot of the global therapeutic scenario for Neuroblastoma. - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuroblastoma pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Neuroblastoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devis

More Info
  • pg 1
									                    Neuroblastoma - Pipeline Review, Q1 2011
                                                                                          Reference Code: GMDHC460IDB

                                                                                          Publication Date: January 2011




Neuroblastoma – Pipeline Review, Q1 2011                                                                              GMDHC460IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                         Page(1)
Neuroblastoma – Pipeline Review, Q1 2011




Ta b le o f Co n te n ts
Table of Contents                                                                                                                            2
List of Tables                                                                                                                               4
List of Figures                                                                                                                              5
Introduction                                                                                                                                 6
     Global Markets Direct Report Coverage                                                                                                   6
Neuroblastoma Overview                                                                                                                       7
Therapeutics Development                                                                                                                     8
     An Overview of Pipeline Products for Neuroblastoma                                                                                      8
Neuroblastoma Therapeutics under Development by Companies                                                                                   10
Neuroblastoma Therapeutics under Investigation by Universities/Institutes                                                                   12
Late Stage Products                                                                                                                         15
     Comparative Analysis                                                                                                                   15
Mid Clinical Stage Products                                                                                                                 16
     Comparative Analysis                                                                                                                   16
Early Clinical Stage Products                                                                                                               17
     Comparative Analysis                                                                                                                   17
Pre-Clinical Stage Products                                                                                                                 18
     Comparative Analysis                                                                                                                   18
Companies Involved in Neuroblastoma Therapeutics Development                                                                                19
     United Therapeutics Corporation                                                                                                        19
     Biotec Pharmacon ASA                                                                                                                   19
     Santaris Pharma A/S                                                                                                                    20
     Geron Corporation                                                                                                                      20
     Merck KGaA                                                                                                                             21
     Ariad Pharmaceuticals, Inc.                                                                                                            21
     Molecular Insight Pharmaceuticals, Inc.                                                                                                22
     Baylor College of Medicine                                                                                                             22
     Neotropix, Inc.                                                                                                                        23
     Archer Biosciences, Inc                                                                                                                23
Universities/Institutes Involved in Neuroblastoma Therapeutics Development                                                                  24
Neuroblastoma Therapeutics Assessment                                                                                                       28
     Assessment by Monotherapy Products                                                                                                     28
     Assessment by Combination Products                                                                                                     29
     Assessment by Route of Administration                                                                                                  30
     Assessment by Molecule Type                                                                                                            32
Late Stage Drug Profiles – Universities/Institutes                                                                                          34
     Carboplatin + Etoposide + Melphalan + Autologous Stem cell infusion - Drug Profile                                                     34
          Product Description                                                                                                               34
          Mechanism of Action                                                                                                               34
          R&D Progress                                                                                                                      34
     Carboplatin + Etoposide + Melphalan + Stem Cell Infusion - Drug Profile                                                                35
          Product Description                                                                                                               35
          Mechanism of Action                                                                                                               35
          R&D Progress                                                                                                                      36
     Filgrastim + Busulfan + Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide phosphate + Melphalan + Vincristine sulfate
     + Radiation therapy - Drug Profile                                                                                                     37
          Product Description                                                                                                               37


Neuroblastoma – Pipeline Review, Q1 2011                                                                     GMDHC460IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                          Page(2)
Neuroblastoma – Pipeline Review, Q1 2011


          Mechanism of Action                                                                                                                 38
          R&D Progress                                                                                                                        39
     filgrastim + carboplatin + cisplatin + cyclophosphamide + dacarbazine + doxorubicin hydrochloride + etoposide phosphate + ifosfamide +
     isotretinoin + melphalan + topotecan hydrochloride + vincristine sulfate + vindesine - Drug Profile                                      41
          Product Description                                                                                                                 41
          Mechanism of Action                                                                                                                 42
          R&D Progress                                                                                                                        44
     Filgrastim + Monoclonal antibody Ch14.18 + Busulfan + Carboplatin + Cyclophosphamide + Etoposide + Isotretinoin + Melphalan + Vincristine
     sulfate - Drug Profile                                                                                                                  45
          Product Description                                                                                                                 45
          Mechanism of Action                                                                                                                 46
          R&D Progress                                                                                                                        46
     vincristine + cisplatin + etoposide + cyclophosphamide + carboplatin - Drug Profile                                                      48
          Product Description                                                                                                                 48
          Mechanism of Action                                                                                                                 48
          R&D Progress                                                                                                                        49
     Neuroblastoma - Featured News                                                                                                            50
          Oct 05, 2010: Enzon Announces Preclinical Study Data Of PEG-SN38 In Pediatric Neuroblastoma                                         50
          May 17, 2010: Publication In The Journal Of The National Cancer Institute Demonstrates KRX-0401 (Perifosine) Single-Agent Potential In
          Neuroblastoma Tumors                                                                                                                 51
          Apr 20, 2010: Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Preclinical Activity Of Single-Agent KRX-0401
          (Perifosine) At 2010 AACR Annual Meeting                                                                                            51
Appendix                                                                                                                                      52
     Methodology                                                                                                                              52
          Coverage                                                                                                                            52
          Secondary Research                                                                                                                  52
          Primary Research                                                                                                                    52
          Expert Panel Validation                                                                                                             53
     Contact Us                                                                                                                               53
     Disclaimer                                                                                                                               53




Neuroblastoma – Pipeline Review, Q1 2011                                                                      GMDHC460IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                       Page(3)
Neuroblastoma – Pipeline Review, Q1 2011




Lis t o f Ta b le s
Number of Products Under Development for Neuroblastoma, 2011                                                   8

Products under Development for Neuroblastoma – Comparative Analysis, 2011                                      9

Comparative Analysis by Late Stage Development, 2011                                                          15

Comparative Analysis by Mid Clinical Stage Development, 2011                                                  16

Comparative Analysis by Early Clinical Stage Development, 2011                                                17

Comparative Analysis by Pre-Clinical Stage Development, 2011                                                  18

United Therapeutics Corporation, 2011                                                                         19

Biotec Pharmacon ASA, 2011                                                                                    19

Santaris Pharma A/S, 2011                                                                                     20

Geron Corporation, 2011                                                                                       20

Merck KGaA, 2011                                                                                              21

Ariad Pharmaceuticals, Inc., 2011                                                                             21

Molecular Insight Pharmaceuticals, Inc., 2011                                                                 22

Baylor College of Medicine, 2011                                                                              22

Neotropix, Inc., 2011                                                                                         23

Archer Biosciences, Inc, 2011                                                                                 23

Assessment by Monotherapy Products, 2011                                                                      28

Assessment by Combination Products                                                                            29

Assessment by Stage and Route of Administration, 2011                                                         31

Assessment by Molecule Type, 2011                                                                             33


								
To top